Randomized controlled trial of transoral incisionless fundoplication Vs. proton pump inhibitors for treatment of gastroesophageal reflux disease

American Journal of Gastroenterology

Volumn 110, Issue 4, 2015, Pages 531-542

  Witteman, Bart P L ^a,b   Conchillo, Jose M ^a   Rinsma, Nicolaas F ^a   Betzel, Bark ^b   Peeters, Andrea ^a   Koek, Ger H ^a   Stassen, Laurents P S ^a   Bouvy, Nicole D ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BODY MASS; CHRONIC DISEASE; CONTROLLED STUDY; DRUG DEPENDENCE; ENDOSCOPY; ESOPHAGUS FUNCTION DISORDER; EXPOSURE; FEMALE; GASTROESOPHAGEAL REFLUX; HEALING; HIATUS HERNIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; STOMACH FUNDOPLICATION; STOMACH PH; THERAPY EFFECT; TRANSORAL INCISIONLESS FUNDOPLICATION; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FOLLOW UP; GASTROSCOPY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FOLLOW-UP STUDIES; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HUMANS; MIDDLE AGED; PROTON PUMP INHIBITORS; QUALITY OF LIFE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84927785579     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.28     Document Type: Article

References (70)

1. Vakil N, Van Zanten SV, Kahrilas P. et al the Montreal defi nition and classifi cation of gastroesophageal refl ux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20. quiz 1943.
2. Stylopoulos N, Rattner DW the history of hiatal hernia surgery: from Bowditch to laparoscopy. Ann Surg 2005; 241: 185-93.
3. Jones MP, Sloan SS, Rabine JC. et al. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal refl ux disease. Am J Gastroenterol 2001; 96: 1711-7.
4. Mittal RK. Hiatal hernia: myth or reality?. Am J Med 1997; 103: 33S-39S
5. Mittal RK. Hiatal hernia and gastroesophageal refl ux: another attempt to resolve the controversy. Gastroenterol 1993; 105: 941-3.
6. Moss SF, Kidd M, Modlin IM the status of the hiatus: the role of hernia in gastroesophageal refl ux disease. J Clin Gastroenterol 2007; 41: S144-S153.
7. Rydberg L, Ruth M, Lundell L. Mechanism of action of antirefl ux procedures. Br J Surg 1999; 86: 405-10.
8. El-Serag HB. Time trends of gastroesophageal refl ux disease: a systematic review. Clin Gastroenterol Hepatol 2007; 5: 17-26.
9. Lundell L. Surgery of gastroesophageal refl ux disease: a competitive or complementary procedure?. Dig Dis 2004; 22: 161-70.
10. Metz DC. Managing gastroesophageal refl ux disease for the lifetime of the patient: evaluating the long-term options. Am J Med 2004; 117 Suppl 5A: 49S-55S
11. Moayyedi P, Talley NJ. Gastro-oesophageal refl ux disease. Lancet 2006; 367: 2086-100.
12. Nandurkar S, Talley NJ. Epidemiology and natural history of refl ux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 743-57.
13. Smout AJ the patient with GORD and chronically recurrent problems. Best Pract Res Clin Gastroenterol 2007; 21: 365-78.
14. Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal refl ux disease: putative mechanisms of failure. Drugs 2007; 67: 1521-30.
15. Gerson LB, Boparai V, Ullah N. et al. Oesophageal and gastric pH profi les in patients with gastro-oesophageal refl ux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004; 20: 637-43.
16. Lundell L, Miettinen P, Myrvold HE. et al. Continued (5-year) followup of a randomized clinical study comparing antirefl ux surgery and omeprazole in gastroesophageal refl ux disease. J Am Coll Surg 2001; 192: 172-9. discussion 179-181.
17. Anvari M, Allen C, Marshall J. et al. A randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal refl ux disease: one-year follow-up. Surg Innov 2006; 13: 238-49.
18. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal refl ux disease in veterans the Department of Veterans Aff airs Gastroesophageal Refl ux Disease Study Group. N Engl J Med 1992; 326: 786-92.
19. Spechler SJ, Lee E, Ahnen D. et al. Long-term outcome of medical and surgical therapies for gastroesophageal refl ux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331-8.
20. Allgood PC, Bachmann M. Medical or surgical treatment for chronic gastrooesophageal refl ux?. A systematic review of published evidence of eff ectiveness. Eur J Surg 2000; 166: 713-21.
21. Cookson R, Flood C, Koo B. et al. Short-term cost eff ectiveness and longterm cost analysis comparing laparoscopic Nissen fundoplication with proton-pump inhibitor maintenance for gastro-oesophageal refl ux disease. Br J Surg 2005; 92: 700-6.
22. Lundell L, Miettinen P, Myrvold HE. et al. Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for refl ux oesophagitis. Br J Surg 2007; 94: 198-203.
23. Mahon D, Rhodes M, Decadt B. et al. Randomized clinical trial of laparoscopic Nissen fundoplication compared with proton-pump inhibitors for treatment of chronic gastro-oesophageal refl ux. Br J Surg 2005; 92: 695-9.
24. Dallemagne B, Weerts J, Markiewicz S. et al. Clinical results of laparoscopic fundoplication at ten years aft er surgery. Surg Endosc 2006; 20: 159-65.
25. Coelho JC, Wiederkehr JC, Campos AC. et al. Conversions and complications of laparoscopic treatment of gastroesophageal refl ux disease. J Am Coll Surg 1999; 189: 356-61.
26. Kamolz T, Granderath FA, Bammer T. et al. Dysphagia and quality of life aft er laparoscopic Nissen fundoplication in patients with and without prosthetic reinforcement of the hiatal crura. Surg Endosc 2002; 16: 572-7.
27. Lundell L. Complications aft er anti-refl ux surgery. Best Pract Res Clin Gastroenterol 2004; 18: 935-45.
28. Wills VL, Hunt DR. Dysphagia aft er antirefl ux surgery. Br J Surg 2001; 88: 486-99.
29. Bessell JR, Finch R, Gotley DC. et al. Chronic dysphagia following laparoscopic fundoplication. Br J Surg 2000; 87: 1341-5.
30. Hayden J, Jamieson G. Optimization of outcome aft er laparoscopic antirefl ux surgery. ANZ J Surg 2006; 76: 258-63.
31. Cadiere GB, Rajan A, Rqibate M. et al. Endoluminal fundoplication (ELF)-evolution of EsophyXTM, a new surgical device for transoral surgery. Minim Invasive Ther Allied Technol 2006; 15: 348-55.
32. Cadiere GB, Rajan A, Germay O. et al. Endoluminal fundoplication by a transoral device for the treatment of GERD: a feasibility study. Surg Endosc 2008; 22: 333-42.
33. Cadiere GB, Buset M, Muls V. et al. Antirefl ux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 2008; 32: 1676-88.
34. Hoppo T, Immanuel A, Schuchert M. et al. Transoral incisionless fundoplication 2.0 procedure using EsophyX for gastroesophageal refl ux disease. J Gastrointest Surg 2010; 14: 1895-901.
35. Furnee EJ, Broeders JA, Draaisma WA. et al. Laparoscopic Nissen fundoplication aft er failed EsophyX fundoplication. Br J Surg 2011; 97: 1051-5.
36. Witteman BP, Strijkers R, de Vries E. et al. Transoral incisionless fundoplication for treatment of gastroesophageal refl ux disease in clinical practice. Surg Endosc 2012; 26: 3307-15.
37. Witteman BP, Kessing BF, Snijders G. et al. Revisional laparoscopic antirefl ux surgery aft er unsuccessful endoscopic fundoplication. Surg Endosc 2013; 27: 2231-6.
38. Velanovich V, Vallance SR, Gusz JR. et al. Quality of life scale for gastroesophageal refl ux disease. J Am Coll Surg 1996; 183: 217-24.
39. Kahrilas PJ, Sifrim D. High-resolution manometry and impedance-pH/manometry: valuable tools in clinical and investigational esophagology. Gastroenterology 2008; 135: 756-69.
40. Conchillo JM, Schwartz MP, Selimah M. et al. Acid and non-acid refl ux patterns in patients wiTherosive esophagitis and non-erosive refl ux disease (NERD): a study using intraluminal impedance monitoring. Dig Dis Sci 2008; 53: 1 506-12
41. Bredenoord AJ. Impedance-pH monitoring: new standard for measuring gastro-oesophageal refl ux. Neurogastroenterol Motil 2008; 20: 434-9.
42. Zerbib F, Roman S, Ropert A. et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006; 101: 1956-63.
43. Sifrim D, Dupont L, Blondeau K. et al. Weakly acidic refl ux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut 2005; 54: 449-54.
44. Bernhard A, Pohl D, Fried M. et al. Infl uence of bolus consistency and position on esophageal high-resolution manometry fi ndings. Dig Dis Sci 2008; 53: 1198-205.
45. Bredenoord AJ, Smout AJ. High-resolution manometry. Dig Liver Dis 2008; 40: 174-81.
46. Fox MR, Bredenoord AJ. Oesophageal high-resolution manometry: moving from research into clinical practice. Gut 2008; 57: 405-23.
47. Jobe BA, Kahrilas PJ, Vernon AH. et al. Endoscopic appraisal of the gastroesophageal valve aft er antirefl ux surgery. Am J Gastroenterol 2004; 99: 233-43.
48. Hill LD, Kozarek RA, Kraemer SJ. et al the gastroesophageal fl ap valve: in vitro and in vivo observations. Gastrointest Endosc 1996; 44: 541-7.
49. Jobe BA, O'Rourke RW, McMahon BP. et al. Transoral endoscopic fundoplication in the treatment of gastroesophageal refl ux disease: the anatomic and physiologic basis for reconstruction of the esophagogastric junction using a novel device. Ann Surg 2008; 248: 69-76.
50. Bell RC, Cadiere GB. Transoral rotational esophagogastric fundoplication: technical, anatomical, and safety considerations. Surg Endosc 2011; 25: 2387-99.
51. Kulich KR, Madisch A, Pacini F. et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Refl ux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes 2008; 6: 12.
52. Jafri SM, Arora G, Triadafi lopoulos G. What is left of the endoscopic antirefl ux devices?. Curr Opin Gastroenterol 2009; 25: 352-7.
53. Repici A, Fumagalli U, Malesci A. et al. Endoluminal fundoplication (ELF) for GERD using EsophyX: a 12-month follow-up in a single-center experience. J Gastrointest Surg 2010; 14: 1-6.
54. Testoni PA, Corsetti M, Di Pietro S. et al. effect of transoral incisionless fundoplication on symptoms, PPI use, and ph-impedance refl uxes of GERD patients. World J Surg 2010; 34: 750-7.
55. Velanovich V. Endoscopic, endoluminal fundoplication for gastroesophageal refl ux disease: initial experience and lessons learned. Surgery 2010; 148: 646-51. discussion 651-3.
56. Demyttenaere SV, Bergman S, Pham T. et al. Transoral incisionless fundoplication for gastroesophageal refl ux disease in an unselected patient population. Surg Endosc 2010; 24: 854-8.
57. Bell RC, Freeman KD. Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal refl ux disease. Surg Endosc 2011; 25: 1975-84.
58. Barnes WE, Hoddinott KM, Mundy S. et al. Transoral incisionless fundoplication off ers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in community practice. Surg Innov 2011; 18: 119-29.
59. Trad KS, Turgeon DG, Deljkich E. Long-term outcomes aft er transoral incisionless fundoplication in patients with GERD and LPR symptoms. Surg Endosc 2012; 26: 650-60.
60. Petersen RP, Filippa L, Wassenaar EB. et al. Comprehensive evaluation of endoscopic fundoplication using the EsophyX device. Surg Endosc 2012; 26: 1021-7.
61. Narsule CK, Burch MA, Ebright MI. et al. Endoscopic fundoplication for the treatment of gastroesophageal refl ux disease: initial experience. J Th orac Cardiovasc Surg 2012; 143: 228-34.
62. Bell RC, Mavrelis PG, Barnes WE. et al. A prospective multicenter registry of patients with chronic gastroesophageal refl ux disease receiving transoral incisionless fundoplication. J Am Coll Surg 2012; 215: 794-809.
63. Muls V, Eckardt AJ, Marchese M. et al. Th ree-year results of a multicenter prospective study of transoral incisionless fundoplication. Surg Innov 2012; 20: 321-30.
64. Bergman S, Mikami DJ, Hazey JW. et al. Endolumenal fundoplication with EsophyX: the initial North American experience. Surg Innov 2008; 15: 166-70.
65. Testoni PA, Vailati C, Testoni S. et al. Transoral incisionless fundoplication (TIF 2.0) with EsophyX for gastroesophageal refl ux disease: long-term results and fi ndings aff ecting outcome. Surg Endosc 2010; 26: 1425-35.
66. Broeders JA, Mauritz FA, Ahmed Ali U. et al. Systematic review and metaanalysis of laparoscopic Nissen (posterior total) versus Toupet (posterior partial) fundoplication for gastro-oesophageal refl ux disease. Br J Surg 2010; 97: 1318-30.
67. Schiefk e I, Zabel-Langhennig A, Neumann S. et al. Long term failure of endoscopic gastroplication (EndoCinch). Gut 2005; 54: 752-8.
68. Pearl JP, Marks JM. Endolumenal therapies for gastroesophageal refl ux disease: are they dead?. Surg Endosc 2007; 21: 1-4.
69. Miner Jr. PB. Review article: physiologic and clinical eff ects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal refl ux. Aliment Pharmacol Ther 2006; 23 Suppl 1: 25-32
70. Dent J, Kahrilas PJ, Vakil'N. et al. Clinical trial design in adult refl ux disease: a methodological workshop. Aliment Pharmacol Ther 2008; 28: 107-26.